HIV-1 Group O Reverse Transcriptase Mutations for High-Temperature Activity

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current reverse transcriptases used in biotechnological applications, such as RT-PCR, face limitations in thermal stability and fidelity at elevated temperatures, particularly above 52 °C, which affects the amplification of RNAs with secondary structures or G:C-rich sequences.

Innovation Solution

Development of reverse transcriptases from HIV-1 group O with specific amino acid modifications, including K358R/A359G/S360A, T69SSG/K358R/A359G/S360A, T355A/Q357M/K358R/A359G/S360A, and E478Q, which exhibit enhanced thermostability and fidelity, allowing for efficient DNA synthesis at temperatures exceeding 75 °C, expressed and purified in bacteria like Escherichia coli.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Temperature

If conventional reverse transcriptases (AMV RT, MLV RT) are used for RNA amplification, then they can perform reverse transcription at moderate temperatures (42-52 °C), but they lose activity and thermal stability at elevated temperatures above 52 °C

Engineering Contradiction:
Improveoperating temperature rangeVSAvoidenzyme activity and thermal stability
Core Design Contradiction:
TemperatureVSReliability

Solution Approach 1:

The patent applies parameter changes by modifying the amino acid sequence of the reverse transcriptase enzyme through site-directed mutagenesis. Specific mutations (K358R, A359G, S360A, T69SSG, T355A, Q357M, E478Q) were introduced to alter the enzyme's thermal stability parameters, enabling it to maintain activity at elevated temperatures up to 75-80 °C while preserving its catalytic function

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite enzyme structure by combining multiple mutations within the reverse transcriptase protein. The synergistic effect of seven different amino acid substitutions produces an enzyme with enhanced thermostability that exceeds the sum of individual mutation effects, achieving superior thermal resistance while maintaining catalytic activity

Inventive Principle:
Principle #40Composite materials

2Temperature

If HIV-1 group O reverse transcriptase with mutations K358R/A359G/S360A is used, then thermostability and activity at elevated temperatures are improved, but the enzyme structure is modified

Engineering Contradiction:
Improveactivity at elevated temperaturesVSAvoidamino acid sequence fidelity
Core Design Contradiction:
TemperatureVSStability of the object's composition

Solution Approach 1:

The patent applies local quality by introducing mutations at specific localized positions within the reverse transcriptase protein structure. The seven mutation sites are strategically distributed across different functional domains, with each location carefully selected to enhance thermal stability without disrupting critical catalytic residues or substrate binding regions

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent changes physical-chemical parameters of the enzyme by substituting amino acids with different properties. For example, K358R changes a basic residue to another basic residue with different stability properties, while T69SSG inserts additional residues to strengthen local structure, collectively enhancing thermostability while preserving function

Inventive Principle:
Principle #35Parameter changes

3Adaptability or versatility

If reverse transcriptases are used for RNAs with secondary structures or G:C-rich sequences, then amplification of these difficult templates is needed, but conventional enzymes lack sufficient activity at the high temperatures required to melt these structures

Engineering Contradiction:
Improveability to amplify difficult RNA templatesVSAvoidtemperature required for template melting
Core Design Contradiction:
Adaptability or versatilityVSTemperature

Solution Approach 1:

The patent changes the operational temperature parameter of the reverse transcriptase enzyme through structural modifications. The mutated enzyme maintains catalytic activity at temperatures up to 75-80 °C, which is sufficient to melt secondary structures and G:C-rich sequences, enabling amplification of difficult RNA templates that conventional enzymes cannot process

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent applies preliminary action by performing reverse transcription at elevated temperatures before PCR amplification. The thermostable reverse transcriptase first synthesizes cDNA from the difficult RNA template at high temperature (75-80 °C), melting secondary structures in advance, and then the resulting cDNA is amplified by conventional PCR, achieving successful amplification of templates that would otherwise be refractory

Inventive Principle:
Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These modified reverse transcriptases demonstrate increased activity and maintained fidelity at high temperatures, improving the yield and accuracy of nucleic acid amplification, especially for RNAs with secondary structures, thereby enhancing biotechnological applications like RT-PCR and sequencing.

Implementation Method 1

reverse transcriptases isolated from a human immunodeficiency virus type 1 group O (HIV-1) and modified in one or more positions that have higher thermostability than the original enzyme, maintaining copying fidelity

Methodology Applied
Scientific EffectEnzyme catalysis: Enzyme

Implementation Method 2

RT converts the single-stranded RNA genome into double-stranded DNA capable of integration into the genome of the host cell

Methodology Applied
Scientific EffectReverse transcription: Enzyme

Data Source

PatentEP2998394B1HIV type 1 group o reverse transcriptases that are active at high temperatures
Publication Date: 2018.06.06 CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
  • EP2998394B1 patent drawingFigure 1A
  • EP2998394B1 patent drawingFigure 1B
  • EP2998394B1 patent drawingFigure 2

AI summary

The present invention falls within the field of biotechnology. More specifically, the invention relates to reverse transcriptases expressed and purified in bacteria and having the amino acid sequence of the reverse transcriptase of a human immunodeficiency virus type 1 (HIV-1) group O, modified at positions 358, 359 and 360; and variants of this enzyme that contain additional changes at positions 355 and 357 or at 478 or position 69 (in this case accompanied by an insertion of two amino acids). These polymerases have greater activity than the non-mutated enzyme at high temperatures (above 60 C). In addition, they retain the capacity for DNA synthesis at temperatures greater than 70 C. Moreover, the copying fidelity of these enzymes is not significantly different from that of the non-mutated reverse transcriptase